leisure time -WSS

leisure time

author：explore 2025-09-07 06:41:12 - browse：83787

illustration of one blue dna strand — Adobe

The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： ASCO Daily Recap: CAR

explore

WSS

Senators tussle over abortion against the backdrop of a presidential campaign

My superpower is killing ticks

STAT wants to know your pick for a great summer read or listen

Stem cell clinics for heart failure: buyer be wary

A new initiative will help leaders fight the next pandemic

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Wikipedia

leisure time

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Peter Hotez and the public health issue of online harassment

FTC loses bid to block Novant's North Carolina hospital merger

Jerome Adams on the need for new antivirals for Covid

Dramatically reducing cancer deaths requires the PASTEUR Act

After affirmative action ruling, medical educators look to 'holistic review'

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

BioMarin wins approval for gene therapy to treat hemophilia A

How CO2 helps viruses stay alive longer in the air

entertainment

The drug industry sees a key ally in the Senate prevail

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Verily hires former Apple Health leader as chief scientific officer

'Ancient DNA,' 23andMe reveal African American ancestries

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

entertainment

explore

explore

explore